Cargando…
Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study
BACKGROUND: The development of systemic chemotherapy including immune checkpoint inhibitors (ICIs) has provided patients with unresectable advanced non-small cell lung cancer (NSCLC) an opportunity to undergo surgical intervention after initial treatment. However, no consensus regarding the indicati...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360220/ https://www.ncbi.nlm.nih.gov/pubmed/37475037 http://dx.doi.org/10.1186/s13019-023-02310-5 |
_version_ | 1785076054956703744 |
---|---|
author | Higuchi, Mitsunori Inomata, Sho Yamaguchi, Hikaru Saito, Takuro Suzuki, Hiroyuki |
author_facet | Higuchi, Mitsunori Inomata, Sho Yamaguchi, Hikaru Saito, Takuro Suzuki, Hiroyuki |
author_sort | Higuchi, Mitsunori |
collection | PubMed |
description | BACKGROUND: The development of systemic chemotherapy including immune checkpoint inhibitors (ICIs) has provided patients with unresectable advanced non-small cell lung cancer (NSCLC) an opportunity to undergo surgical intervention after initial treatment. However, no consensus regarding the indication for salvage surgery in these patients has been reached. METHODS: We conducted a retrospective study of patients who underwent salvage surgery for advanced NSCLC (cStage IIIA–IVB) after treatment with ICIs from January 2018 to December 2022 at Aizu Medical Center and Fukushima Medical University Hospital. We evaluated the patients’ clinical data, calculated disease-free survival (DFS) and overall survival (OS), and assessed the survival benefit using the Kaplan–Meier method. RESULTS: Thirteen patients underwent salvage surgery after immunotherapy. All patients achieved downstaging after initial chemotherapy. Eleven patients underwent lobectomy, and one patient underwent extirpation of intra-abdominal lymph nodes. The mean surgery time and intraoperative blood loss were 242.2 min and 415.1 g, respectively. The mean drainage period was 4.2 days (range, 2–9 days). Grade ≥ 3 postoperative complications were confirmed in three patients. The 2-year DFS rate was 71.2%, and the 2-year OS rate was 76.2%. A pathological complete response compatible with ypStage 0 was achieved in four (30.8%) patients. Patients with ypStage 0 and I achieved significantly better OS than those with ypStage ≥ II (p = 0.044), and patients without severe complications achieved significantly better DFS and OS than those with severe complications (p = 0.001 and p < 0.001, respectively). CONCLUSIONS: Salvage surgery after chemotherapy including ICIs is a feasible and effective treatment option for patients with advanced NSCLC, especially those who acquire downstaging to pathological stage 0 or I. However, severe perioperative complications might affect patient survival. A prospective study is urgently needed to evaluate the efficacy of salvage surgery. |
format | Online Article Text |
id | pubmed-10360220 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-103602202023-07-22 Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study Higuchi, Mitsunori Inomata, Sho Yamaguchi, Hikaru Saito, Takuro Suzuki, Hiroyuki J Cardiothorac Surg Research BACKGROUND: The development of systemic chemotherapy including immune checkpoint inhibitors (ICIs) has provided patients with unresectable advanced non-small cell lung cancer (NSCLC) an opportunity to undergo surgical intervention after initial treatment. However, no consensus regarding the indication for salvage surgery in these patients has been reached. METHODS: We conducted a retrospective study of patients who underwent salvage surgery for advanced NSCLC (cStage IIIA–IVB) after treatment with ICIs from January 2018 to December 2022 at Aizu Medical Center and Fukushima Medical University Hospital. We evaluated the patients’ clinical data, calculated disease-free survival (DFS) and overall survival (OS), and assessed the survival benefit using the Kaplan–Meier method. RESULTS: Thirteen patients underwent salvage surgery after immunotherapy. All patients achieved downstaging after initial chemotherapy. Eleven patients underwent lobectomy, and one patient underwent extirpation of intra-abdominal lymph nodes. The mean surgery time and intraoperative blood loss were 242.2 min and 415.1 g, respectively. The mean drainage period was 4.2 days (range, 2–9 days). Grade ≥ 3 postoperative complications were confirmed in three patients. The 2-year DFS rate was 71.2%, and the 2-year OS rate was 76.2%. A pathological complete response compatible with ypStage 0 was achieved in four (30.8%) patients. Patients with ypStage 0 and I achieved significantly better OS than those with ypStage ≥ II (p = 0.044), and patients without severe complications achieved significantly better DFS and OS than those with severe complications (p = 0.001 and p < 0.001, respectively). CONCLUSIONS: Salvage surgery after chemotherapy including ICIs is a feasible and effective treatment option for patients with advanced NSCLC, especially those who acquire downstaging to pathological stage 0 or I. However, severe perioperative complications might affect patient survival. A prospective study is urgently needed to evaluate the efficacy of salvage surgery. BioMed Central 2023-07-20 /pmc/articles/PMC10360220/ /pubmed/37475037 http://dx.doi.org/10.1186/s13019-023-02310-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Higuchi, Mitsunori Inomata, Sho Yamaguchi, Hikaru Saito, Takuro Suzuki, Hiroyuki Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study |
title | Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study |
title_full | Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study |
title_fullStr | Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study |
title_full_unstemmed | Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study |
title_short | Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study |
title_sort | salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360220/ https://www.ncbi.nlm.nih.gov/pubmed/37475037 http://dx.doi.org/10.1186/s13019-023-02310-5 |
work_keys_str_mv | AT higuchimitsunori salvagesurgeryforadvancednonsmallcelllungcancerfollowingpreviousimmunotherapyaretrospectivestudy AT inomatasho salvagesurgeryforadvancednonsmallcelllungcancerfollowingpreviousimmunotherapyaretrospectivestudy AT yamaguchihikaru salvagesurgeryforadvancednonsmallcelllungcancerfollowingpreviousimmunotherapyaretrospectivestudy AT saitotakuro salvagesurgeryforadvancednonsmallcelllungcancerfollowingpreviousimmunotherapyaretrospectivestudy AT suzukihiroyuki salvagesurgeryforadvancednonsmallcelllungcancerfollowingpreviousimmunotherapyaretrospectivestudy |